Inhibitor Therapeutics, Inc. financial data

Symbol
INTI on OTC
Industry
Pharmaceutical Preparations
Location
4830 W. Kennedy Blvd., Suite 600, Tampa, FL
State of incorporation
Delaware
Fiscal year end
December 31
Former names
HedgePath Pharmaceuticals, Inc. (to 8/12/2019), COMMONWEALTH BIOTECHNOLOGIES INC (to 5/20/2013)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.31K % +89.2%
Debt-to-equity 63.4 % -12.6%
Return On Equity -58.9 % -125%
Return On Assets -36 % -127%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 172M shares +0.19%
Common Stock, Shares, Outstanding 172M shares +0.21%
Entity Public Float 3.2M USD -59%
Common Stock, Value, Issued 17.2K USD +0.2%
Weighted Average Number of Shares Outstanding, Basic 172M shares +0.21%
Weighted Average Number of Shares Outstanding, Diluted 172M shares +0.21%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 1.42M USD +226%
General and Administrative Expense 1.97M USD +37.9%
Operating Income (Loss) -3.39M USD -81.8%
Net Income (Loss) Attributable to Parent -3.02M USD -127%
Earnings Per Share, Basic -0.02 USD/shares -167%
Earnings Per Share, Diluted -0.02 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.1M USD -29.7%
Assets, Current 7.17M USD -29.4%
Assets 7.17M USD -29.4%
Accounts Payable, Current 18.8K USD +60%
Accrued Liabilities, Current 16.7K USD -47.9%
Liabilities, Current 35.5K USD -19%
Liabilities 3.04M USD -0.27%
Retained Earnings (Accumulated Deficit) -50M USD -6.43%
Stockholders' Equity Attributable to Parent 4.14M USD -41.8%
Liabilities and Equity 7.17M USD -29.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.16M USD -52.9%
Net Cash Provided by (Used in) Financing Activities -411K USD -922%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 172M shares +0.21%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.16M USD +0.87%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.1M USD -29.7%
Deferred Tax Assets, Valuation Allowance 5.45M USD +15.3%
Deferred Tax Assets, Gross 5.45M USD +15.3%
Deferred Tax Assets, Operating Loss Carryforwards 3.52M USD -9.13%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2.25M shares 0%
Additional Paid in Capital 54.1M USD
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 23.2K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%